Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Buccal Carcinoma Workup

  • Author: Christopher Klem, MD; Chief Editor: Arlen D Meyers, MD, MBA  more...
 
Updated: Mar 22, 2016
 

Laboratory Studies

See the list below:

  • General preoperative workup should be based upon multiple factors, especially the extent of the patient's surgery and pre-existing medical conditions. Useful laboratory tests include the following:
    • CBC count, electrolytes, BUN, and creatinine (These provide a general screen for anemia, infection, electrolyte disturbance, and renal abnormalities.)
    • Prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (These are used to screen for coagulopathy.)
    • Liver function and gamma glutamic transpeptidase (GGT) tests (These screen for alcoholic liver damage or distant metastatic disease.)
    • Blood typing and cross-matching (These are indicated for patients with anemia or those undergoing extensive surgery with a risk of significant blood loss.)
Next

Imaging Studies

See the list below:

  • Chest radiographs, to include posteroanterior (PA) and lateral views, which will provide the following:
    • An assessment for pulmonary metastases or a synchronous lung tumor
    • An assessment for chronic lung disease, which is common in patients with head and neck cancer
  • Contrast-enhanced CT scanning or MRI of the primary site and neck is helpful for the following reasons:
    • They provide staging information of both the primary tumor and neck, as well as for treatment planning.
    • They improve the diagnostic yield of physical examination alone in assessing for adenopathy and bone invasion.
    • They allow assessment of the depth and extent of the tumor and are used to evaluate the cervical lymph nodes.
    • They can provide valuable information about the resectability of advanced disease, including the relationship of disease to the carotid artery, cervical spine, and skull base. Bone windows are particularly helpful in assessing bone invasion of the mandible or maxilla.
    • MRI provides better soft-tissue delineation than does CT, and dental artifacts do not affect MRIs. This advantage may be most relevant in cases with posterior spread of the tumor into the masticator space and toward the skull base.
    • MRI can also be used to assess bone invasion by showing marrow replacement on T1-weighted images; however, osteomyelitis, osteoradionecrosis, or previous radiation may produce a similar appearance.
    • They are often complementary.
  • Chest CT scanning and positron emission tomography (PET) may both be used for metastatic workup.
    • Chest CT may be used primarily or secondarily if an abnormality is identified on chest radiographs.
    • PET has an increasing role in the workup of head and neck cancer. Currently, it is supplementary to physical examination and diagnostic imaging techniques such as MRI and CT. PET can be beneficial in confirming the primary tumor and assessing cervical adenopathy and distant metastases.
  • Panorex imaging (mandibular orthopantomography) may be used to evaluate mandibular invasion in conjunction with CT scanning and clinical examination. It is also valuable in dental assessments of patients in whom radiation therapy is considered.
Previous
Next

Diagnostic Procedures

See the list below:

  • Biopsy
    • Any suspicious or nonhealing lesion of the buccal mucosa should be biopsied fro histopathologic examination.
    • Incisional biopsy is useful for most lesions unless they are small enough that excisional biopsy can be done without significant morbidity.
    • Repeat excision with adequate margins may be required if the results of excisional biopsy are positive for carcinoma.
  • Examination under anesthesia and panendoscopy
    • Involves inspection and palpation of the oral cavity and oropharynx, direct laryngoscopic examination of the hypopharynx, larynx, and endoscopic evaluation of the esophagus, trachea, and nasopharynx as indicated.
    • Can often be done at the time of planned resection.
Previous
Next

Histologic Findings

Squamous cell carcinoma is the most common malignancy of the buccal mucosa, accounting for more than 90% of cases. Other less common malignancies include carcinoma arising from minor salivary glands, mucosal melanoma, lymphoma, and Kaposi sarcoma.

Classic histologic features of squamous cell carcinoma include atypical epithelial cells infiltrating the basement membrane, with intercellular bridges and keratin formation depending on the degree of differentiation. Squamous cell carcinoma stains positive for keratin.

Previous
Next

Staging

Buccal carcinoma is staged using the American Joint Commission on Cancer (AJCC) Staging System for the oral cavity. The last modification to this staging system was 2002. Staging is based on findings from clinical examination, endoscopic evaluation, and diagnostic imaging. Staging may be modified on the basis of the pathologic findings.

The tumor, metastases, and nodes (TNM) classification is an expression of the anatomic extent of a primary tumor (T), neck disease (N) and metastases (M). The stage grouping condenses the different TNM combinations into groups, with each stage being homogenous with respect to survival.

  • Primary tumor (T)
    • Tx - Primary tumor cannot be assessed
    • T0 - No evidence of primary tumor
    • Tis - Carcinoma in situ
    • T1 - Tumor no larger than 2 cm in greatest dimension
    • T2 – Tumor larger than 2 cm but smaller than 4 cm in greatest dimension
    • T3 - Tumor larger than 4 cm in greatest dimension
    • T4a - Tumor invading adjacent structures (eg, through cortical bone, into the deep [extrinsic] muscles of the tongue, maxillary sinus, or skin of the face)
    • T4b - Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery
  • Regional lymph nodes
    • NX - Regional lymph nodes cannot be assessed
    • N0 - No regional lymph node metastasis
    • N1 - Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
    • N2a - Metastasis in a single ipsilateral lymph node larger than 3 cm but smaller than 6 cm in greatest dimension
    • N2b - Metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension
    • N2c - Metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension
    • N3 - Metastases in a lymph node larger than 6 cm in greatest dimension
    • Distant metastases
      • MX - Distant metastasis not assessable
      • M0 - No distant metastasis
      • M1 - Distant metastasis
  • Stages are defined as follows:
    • Stage 0 - Tis N0 M0
    • Stage 1 - T1 N0 M0
    • Stage 2 - T2 N0 M0
    • Stage 3 - T3 N0 M0; T1, T2, or T3 N1 M0
    • Stage 4a - T4a N0 M0; T4a N1 M0; T1, T2, T3 or T4a N2 M0
    • Stage 4b – Any T N3 M0; T4b any N M0
    • Stage 4c - Any T any N M1
Previous
 
 
Contributor Information and Disclosures
Author

Christopher Klem, MD Attending Surgeon, Chief, Head and Neck Oncologic Surgery, Microvascular Reconstructive Surgery, Assistant Chief, Otolaryngology–Head and Neck Surgery Service, Tripler Army Medical Center

Christopher Klem, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Medical Association, American Society for Reconstructive Microsurgery

Disclosure: Nothing to disclose.

Coauthor(s)

David P Goldstein, MD, FRCSC, MSc Consulting Staff, Department of Otolaryngology, Division of Head and Neck Oncology and Microvascular Reconstructive Surgery, University Health Network, Toronto

David P Goldstein, MD, FRCSC, MSc is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, Canadian Medical Association, Canadian Society of Otolaryngology-Head & Neck Surgery

Disclosure: Nothing to disclose.

Russell B Smith, MD, FACS Vice Chairman, Professor of Otolaryngology-Head and Neck Surgery, Division of Head and Neck Surgical Oncology, University of Nebraska Medical Center; Consulting Staff, Division of Head and Neck Surgical Oncology, Nebraska Methodist Hospital; Consulting Staff, Veterans Administration Medical Center

Russell B Smith, MD, FACS is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Thyroid Association, Nebraska Medical Association, North American Skull Base Society

Disclosure: Nothing to disclose.

Gerry F Funk, MD Professor, Department of Otolaryngology-Head and Neck Surgery, University of Iowa

Gerry F Funk, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Karen H Calhoun, MD, FACS, FAAOA Professor, Department of Otolaryngology-Head and Neck Surgery, Ohio State University College of Medicine

Karen H Calhoun, MD, FACS, FAAOA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Head and Neck Society, Association for Research in Otolaryngology, Southern Medical Association, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, American Rhinologic Society, Society of University Otolaryngologists-Head and Neck Surgeons, Texas Medical Association

Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA Professor of Otolaryngology, Dentistry, and Engineering, University of Colorado School of Medicine

Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American Head and Neck Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cerescan;RxRevu;SymbiaAllergySolutions<br/>Received income in an amount equal to or greater than $250 from: Symbia<br/>Received from Allergy Solutions, Inc for board membership; Received honoraria from RxRevu for chief medical editor; Received salary from Medvoy for founder and president; Received consulting fee from Corvectra for senior medical advisor; Received ownership interest from Cerescan for consulting; Received consulting fee from Essiahealth for advisor; Received consulting fee from Carespan for advisor; Received consulting fee from Covidien for consulting.

Additional Contributors

Benoit J Gosselin, MD, FRCSC Associate Professor of Surgery, Dartmouth Medical School; Director, Comprehensive Head and Neck Oncology Program, Norris Cotton Cancer Center; Staff Otolaryngologist, Division of Otolaryngology-Head and Neck Surgery, Dartmouth-Hitchcock Medical Center

Benoit J Gosselin, MD, FRCSC is a member of the following medical societies: American Head and Neck Society, American Academy of Facial Plastic and Reconstructive Surgery, North American Skull Base Society, American Academy of Otolaryngology-Head and Neck Surgery, American Medical Association, American Rhinologic Society, Canadian Medical Association, Canadian Society of Otolaryngology-Head & Neck Surgery, College of Physicians and Surgeons of Ontario, New Hampshire Medical Society, Ontario Medical Association

Disclosure: Nothing to disclose.

References
  1. Singhania V, Jayade BV, Anehosur V, Gopalkrishnan K, Kumar N. Carcinoma of buccal mucosa: A site specific clinical audit. Indian J Cancer. 2015 Oct-Dec. 52 (4):605-10. [Medline]. [Full Text].

  2. Diaz EM Jr, Holsinger FC, Zuniga ER, et al. Squamous cell carcinoma of the buccal mucosa: one institution's experience with 119 previously untreated patients. Head Neck. 2003 Apr. 25(4):267-73. [Medline].

  3. Chhetri DK, Rawnsley JD, Calcaterra TC. Carcinoma of the buccal mucosa. Otolaryngol Head Neck Surg. 2000 Nov. 123(5):566-71. [Medline].

  4. Elsurer C, Ozturk K, Baba F, Yavas C, Bulut S. Giant papillary carcinoma arising in the ectopic buccal thyroid tissue. Head Neck. 2012 Sep 10. [Medline].

  5. Giri GV, Thejaswini B, Nanda R, Aradhana K. Prediction of outcome in buccal cancers treated with radical radiotherapy based on the early tumor response. J Cancer Res Ther. 2015 Apr-Jun. 11 (2):364-8. [Medline]. [Full Text].

  6. Bachar G, Goldstein DP, Barker E, Lea J, O'Sullivan B, Brown DH, et al. Squamous cell carcinoma of the buccal mucosa: outcomes of treatment in the modern era. Laryngoscope. 2012 Jul. 122(7):1552-7. [Medline].

  7. Camilon PR, Stokes WA, Fuller CW, et al. Does buccal cancer have worse prognosis than other oral cavity cancers?. Laryngoscope. 2014 Jun. 124(6):1386-91. [Medline].

Previous
Next
 
Early oral squamous cell carcinoma in the buccal mucosa arising from a chronic candidal leukoplakia in a person who smokes heavily. The lesion was a painless, chronic indurated lump.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.